APOBEC3D抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-3: 231, HEPG2 and Jurkat cell lysates, Primary antibody: P04579(APOBEC3D Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P04579(APOBEC3D Antibody) at dilution 1/80. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P04579(APOBEC3D Antibody) at dilution 1/80. (Original magnification: ×200)    

  
  

APOBEC3D is a member of the APOBEC3 (apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3) family of cytidine deaminases, which play critical roles in innate immunity by restricting retroviruses, retrotransposons, and DNA viruses. These enzymes induce hypermutations in viral genomes by converting cytosine to uracil during reverse transcription, thereby disrupting viral replication. APOBEC3D, primarily expressed in immune cells and certain tissues, exhibits weaker antiviral activity compared to other family members like APOBEC3G or APOBEC3F. However, it may synergize with other APOBEC3 proteins to enhance viral restriction or contribute to viral evolution under selective pressure.

Antibodies targeting APOBEC3D are essential tools for studying its expression, subcellular localization, and functional interactions in antiviral defense, cancer biology (e.g., somatic mutagenesis in tumors), and host-pathogen dynamics. They enable detection via techniques like Western blotting, immunofluorescence, and immunoprecipitation. Due to high sequence homology among APOBEC3 family members, developing specific APOBEC3D antibodies requires careful epitope selection and validation using knockout cell lines to avoid cross-reactivity. Such antibodies have advanced research into APOBEC3D's dual roles—acting as a host defense factor while potentially contributing to genomic instability in cancer through off-target DNA editing. Ongoing studies focus on its regulation, post-translational modifications, and therapeutic targeting in viral infections or malignancies.